Abeona Therapeutics heads into its May 13 earnings call with one of the most extreme short setups in the biotech universe — and a 25% monthly price rally making that position increasingly uncomfortable.
Short sellers are deeply dug in. Short interest has climbed to 30% of the free float, up 5.7% over the past week alone after a brief dip in mid-April. The ORTEX short score is 83.5, ranking the stock in the first percentile across all names the platform covers — only a handful of stocks carry heavier relative short pressure. Days to cover is a substantial 18.5 sessions, meaning any forced unwind would play out slowly and painfully. Yet the stock has ignored the bears this month, rallying 25% from its March lows to close at $5.36.
The borrow market tells a more nuanced story. Cost to borrow has actually eased — falling around 16% on the week to 1.08% annualised — suggesting shorts are not scrambling to replace lost inventory just yet. Availability, however, is tight: the lending pool has only just begun to open up slightly, with the 52-week tightest reading having been 93.9% utilised versus today's 90.5%. That thin cushion means any acceleration in demand for borrows could reprice quickly. Options traders have taken a notably bullish turn: the put/call ratio crashed to 0.36 on April 28, nearly two standard deviations below its 20-day mean of 0.50. That's close to the most call-heavy reading in the past year. While short interest is piling up, options positioning has swung hard in the other direction — two signals pointing directly at each other.
The Street is uniformly constructive, though coverage is thin and the most recent analyst action is dated. HC Wainwright reiterated a Buy and $20 target in March, as has been the case repeatedly for well over a year. Oppenheimer carries an Outperform at $20. With the stock at $5.36, those $20 targets imply more than 270% upside — a gap the market clearly does not believe, and one that warrants treating the analyst data as context rather than signal given its age. The bull case rests on pz-cel, the company's gene therapy for recessive dystrophic epidermolysis bullosa, with analysts projecting revenues scaling from roughly $32 million in 2025 to over $130 million by 2026. The bear case centres on slow US adoption, ex-US execution risk, and ongoing dilution pressure.
Insider activity adds one more layer of caution. Every insider transaction recorded over the past 90 days has been a sale. CEO Vishwas Seshadri sold nearly 100,000 shares across two separate transactions — the most recent at the end of March — while the CFO and multiple independent directors also trimmed positions in January and February. The net 90-day insider flow is a disposal of around $1.2 million in stock. None of the individual transactions are enormous relative to the company's float, but the consistency of the selling direction, right across the executive team, is worth noting alongside the bullish analyst framing.
Peer biotech names had a mixed week. TSHA edged up 1.3% over the same period while BCYC and BCAX fell around 5% each. SLXN was the standout mover in the group, shedding 36% on the week. ABEO's relative outperformance — down just 0.4% on the week against a peer group largely in the red — is notable given the weight of short interest overhead.
The May 13 earnings release is the next hard catalyst. Prior prints have been volatile: the March 2026 report saw the stock fall 8% on the day and 12.5% over the following five sessions, while the November 2025 print produced a 8.6% gain that faded entirely within a week. With options skewing sharply bullish and short interest at multi-month highs, the print will quickly resolve which side of this tension is right.
See the live data behind this article on ORTEX.
Open ABEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
